SON-1210
Solid Tumors
Key Facts
About Sonnet BioTherapeutics
Sonnet BioTherapeutics leverages its modular FHAB technology to create a pipeline of cytokine-derived therapies aimed at improving the therapeutic window and efficacy of immunomodulatory drugs in oncology. The company's lead program is in Phase 1 development with a combination study involving Roche's atezolizumab, and it has established collaborations for investigator-initiated trials. Following a recent business combination with Hyperliquid Strategies Inc., the company now trades on the Nasdaq Capital Market under the ticker 'PURR', positioning it to advance its clinical-stage pipeline.
View full company profileAbout Sonnet BioTherapeutics
Sonnet BioTherapeutics leverages its modular FHAB technology to create a pipeline of cytokine-derived therapies aimed at improving the therapeutic window and efficacy of immunomodulatory drugs in oncology. The company's lead program is in Phase 1 development with a combination study involving Roche's atezolizumab, and it has established collaborations for investigator-initiated trials. Following a recent business combination with Hyperliquid Strategies Inc., the company now trades on the Nasdaq Capital Market under the ticker 'PURR', positioning it to advance its clinical-stage pipeline.
View full company profileOther Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-981 | Takeda Pharmaceutical | Phase 1/2 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |
| CSPC-DM02 | CSPC Pharmaceutical Group Limited | Phase 2 |